Loading
TareBio
TareBio reads the immune cells already fighting a cancer in a patient's body and works backwards to design a vaccine that makes more of them, in weeks rather than years.
Overview
TareBio's platform designs personalised or population-level vaccines by reading out the immune imprint, the T and B cells already engaged against a disease in the body, and reverse-engineering antigens that activate them, rather than predicting antigens from tumour sequencing alone. The company reports having run the platform end to end and produced a vaccine that cleared tumours in mice. It is a one-person Summer 2026 YC company; the work is preclinical.
Headquarters
San Francisco, CA, US
Funding
All startupsStartupYC S26
Investors
Type
Stage
Startup · Y Combinator Summer 2026
Website
Connected
4Similar pages
- CompanyGuardian Bio
Shares Y Combinator, Off-the-shelf cancer vaccines and the tag yc.
- CompanyAdventris Pharmaceuticals
Shares Y Combinator, Off-the-shelf cancer vaccines and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator and the tag yc.
- CompanyDelee
Shares Y Combinator and the tag yc.
- CompanyResistanceBio (Viosera Therapeutics)
Shares Y Combinator and the tag yc.
fronts
technologies
companies
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
tarebio.com · 1
ycombinator.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/